JP2016516721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516721A5 JP2016516721A5 JP2016502966A JP2016502966A JP2016516721A5 JP 2016516721 A5 JP2016516721 A5 JP 2016516721A5 JP 2016502966 A JP2016502966 A JP 2016502966A JP 2016502966 A JP2016502966 A JP 2016502966A JP 2016516721 A5 JP2016516721 A5 JP 2016516721A5
- Authority
- JP
- Japan
- Prior art keywords
- difficile
- toxoid
- toxin
- formaldehyde
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 99
- 241000193163 Clostridioides difficile Species 0.000 claims description 73
- 239000000203 mixture Substances 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 48
- 229960005486 vaccine Drugs 0.000 claims description 24
- 101710182223 Toxin B Proteins 0.000 claims description 18
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims description 17
- 101710182532 Toxin a Proteins 0.000 claims description 17
- 238000011534 incubation Methods 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 230000000415 inactivating effect Effects 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 150000005846 sugar alcohols Chemical class 0.000 claims description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790423P | 2013-03-15 | 2013-03-15 | |
| US61/790,423 | 2013-03-15 | ||
| PCT/US2014/029035 WO2014144567A2 (en) | 2013-03-15 | 2014-03-14 | Toxoid, compositions and related methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016516721A JP2016516721A (ja) | 2016-06-09 |
| JP2016516721A5 true JP2016516721A5 (enExample) | 2017-05-18 |
Family
ID=50489430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502966A Pending JP2016516721A (ja) | 2013-03-15 | 2014-03-14 | トキソイド、組成物および関連方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160045586A1 (enExample) |
| EP (1) | EP2968507A2 (enExample) |
| JP (1) | JP2016516721A (enExample) |
| KR (1) | KR20150133770A (enExample) |
| CN (1) | CN105338997A (enExample) |
| AR (1) | AR095669A1 (enExample) |
| AU (1) | AU2014228956A1 (enExample) |
| BR (1) | BR112015023332A2 (enExample) |
| CA (1) | CA2907154A1 (enExample) |
| HK (1) | HK1213800A1 (enExample) |
| SG (1) | SG11201507608PA (enExample) |
| TW (1) | TWI624474B (enExample) |
| WO (1) | WO2014144567A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391236B (es) | 2011-04-22 | 2025-03-21 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos. |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| SG11201510166YA (en) * | 2013-06-14 | 2016-01-28 | Sanofi Pasteur Inc | Compositions and methods of immunizing against c. difficile |
| BR112017024443A2 (pt) * | 2015-05-15 | 2018-10-23 | Sanofi Pasteur Inc | métodos para imunização contra clostridium difficile |
| JP7349366B2 (ja) * | 2017-06-09 | 2023-09-22 | ヒプラ シエンティフィック エセ．エレ．ウ． | クロストリジウム類毒素を含むワクチン |
| US10096313B1 (en) * | 2017-09-20 | 2018-10-09 | Bose Corporation | Parallel active noise reduction (ANR) and hear-through signal flow paths in acoustic devices |
| AU2022408126A1 (en) * | 2021-12-06 | 2024-07-04 | Rutgers, The State University Of New Jersey | Compositions and methods for treating cancer |
| WO2024160901A1 (en) | 2023-02-02 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| US5610023A (en) * | 1995-03-31 | 1997-03-11 | Lee Laboratories, Inc. | Method of purification of clostridium difficile toxin A and production of mono-specific antibodies |
| DE69829400T2 (de) * | 1997-10-20 | 2006-04-13 | Acambis, Inc., Cambridge | Passive immunisierung gegen durch clostridium difficile verursachte krankheit |
| US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| US6669520B2 (en) | 2001-09-19 | 2003-12-30 | United Microelectronics Corp. | Method of fabricating an LC panel |
| AU2008280755B9 (en) | 2007-07-26 | 2014-09-25 | Sanofi Pasteur Limited | Antigen-adjuvant compositions and methods |
| WO2009035707A1 (en) | 2007-09-14 | 2009-03-19 | Acambis Inc. | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
| GB201011968D0 (en) * | 2010-07-16 | 2010-09-01 | Secr Defence | Toxoiding method |
-
2014
- 2014-03-14 US US14/776,145 patent/US20160045586A1/en not_active Abandoned
- 2014-03-14 EP EP14717950.1A patent/EP2968507A2/en not_active Withdrawn
- 2014-03-14 CN CN201480021368.4A patent/CN105338997A/zh active Pending
- 2014-03-14 WO PCT/US2014/029035 patent/WO2014144567A2/en not_active Ceased
- 2014-03-14 AU AU2014228956A patent/AU2014228956A1/en not_active Abandoned
- 2014-03-14 HK HK16101854.5A patent/HK1213800A1/zh unknown
- 2014-03-14 SG SG11201507608PA patent/SG11201507608PA/en unknown
- 2014-03-14 KR KR1020157029566A patent/KR20150133770A/ko not_active Withdrawn
- 2014-03-14 BR BR112015023332A patent/BR112015023332A2/pt not_active IP Right Cessation
- 2014-03-14 JP JP2016502966A patent/JP2016516721A/ja active Pending
- 2014-03-14 CA CA2907154A patent/CA2907154A1/en not_active Abandoned
- 2014-03-17 TW TW103110044A patent/TWI624474B/zh not_active IP Right Cessation
- 2014-03-18 AR ARP140101275A patent/AR095669A1/es unknown
-
2017
- 2017-10-02 US US15/722,029 patent/US20180028637A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516721A5 (enExample) | ||
| MX2022009429A (es) | Composiciones para la inmunizacion contra virus respiratorios. | |
| ZA201904307B (en) | Polypeptide-antigen conjugates with non-natural amino acids | |
| PH12017501445A1 (en) | Methods for producing virus for vaccine production | |
| PH12018500856A1 (en) | Respiratory syncytial virus vaccine | |
| NZ622731A (en) | Increasing virus-like particle yield in plants | |
| PH12015500633A1 (en) | Method for preparing imp fermented broth or glutamic acid fermented broth as raw material for preparation of natural flavor | |
| NZ616304A (en) | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses | |
| MX390947B (es) | Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas. | |
| MY165831A (en) | Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with a improved immunogenicity | |
| MA32819B1 (fr) | Vaccin combine notamment contre la coqueluche acellulaire | |
| UA110024C2 (uk) | Вакцинний вектор і спосіб посилення імунної відповіді | |
| MY173223A (en) | Method of making a mycoplasma vaccine | |
| WO2011043584A3 (ko) | 형질전환 식물 유래의 고병원성 조류독감 바이러스 단백질 백신 및 그 제조방법 | |
| PH12020550976A1 (en) | Camp receptor protein variant and method of producing l-amino acid using the same | |
| MX2020005554A (es) | Vacunas y composiciones inmunogenas para zika y metodos para usarlas. | |
| MX385961B (es) | Un método para la activación de bacterias de ácido láctico. | |
| GEP20247684B (en) | Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same | |
| RU2014146772A (ru) | Новые ротавирусные вакцинные композиции и способ получения вышеуказанных композиций | |
| RU2017141773A (ru) | Микроорганизм рода Escherichia, продуцирующий L-триптофан, и способ получения L-триптофана с его использованием | |
| MX2021011913A (es) | Composiciones de virus inactivado y formulaciones de vacunas contra el zika. | |
| RU2012108227A (ru) | Вакцина, направленная против актинобациллезной плевропневмонии, и способ получения такой вакцины | |
| WO2023235660A3 (en) | Flavivirus immunogens and vaccine compositions and methods of using the same | |
| CN113350497A (zh) | 一种混合麻疹减毒疫苗的新冠肺炎疫苗 | |
| MX2017005080A (es) | Preparacion de citrato de zinc y composiciones para cuidado oral que contienen citrato de zinc. |